[1]李子进,综述,李景东,等.锚蛋白B在心血管系统中作用的研究进展[J].心血管病学进展,2016,(4):341-344.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.004]
　LI Zijin,LI Jingdong.Research Progress of Ankyrin-B in Cardiovascular System[J].Advances in Cardiovascular Diseases,2016,(4):341-344.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.004]
点击复制

锚蛋白B在心血管系统中作用的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2016年4期
页码:
341-344
栏目:
主题综述
出版日期:
2016-08-15

文章信息/Info

Title:
Research Progress of Ankyrin-B in Cardiovascular System
作者:
李子进1; 综述; 李景东1; 2; 审校
1.华中科技大学同济医学院,湖北 武汉430022; 2.华中科技大学同济医学院附属协和医院心内科,湖北 武汉 430022
Author(s):
LI Zijin1; LI Jingdong1; 2
1. Huazhong University of Science and Technology,Wuhan 430022,Hubei,China; 2.Department of Cardiology,Union Hospital,Tongji Medical College, Huazhong University of Science and Technology,Wuhan 430022,Hubei,China
关键词:
锚蛋白;  离子通道;  跨膜蛋白;  心律失常;  心血管疾病
Keywords:
Ankyrin;  Ion channels;  Transporters;  Arrhythmias;  Cardiovascular disorders
分类号:
R54
DOI:
10.16806/j.cnki.issn.1004-3934.2016.04.004
文献标志码:
A
摘要:
锚蛋白家族是重要的整合蛋白,参与心血管系统中离子通道、跨膜蛋白在细胞膜上的固定及适当表达和功能维持。锚蛋白通路的缺陷可以导致离子通道和跨膜复合物的功能异常并引发致死性心律失常,如锚蛋白B综合征。近来研究还发现锚蛋白B的水平在心肌梗死后及窦房结病变中有显著变化,提示锚蛋白B与人类心血管疾病密切相关。对锚蛋白的研究为了解人类心血管疾病提供了新的分子机制。现就近年来锚蛋白B在心血管系统的研究进展做扼要概括。
Abstract:
Ankyrins are a family of “adaptor” proteins, and play critical roles in the proper expression and membrane localization of ion channels and as transporters in the cardiovascular system.Dysfunction in ankyrin-based pathways has been linked with abnormal ion channel and transporter membrane organization and fatal human arrhythmias, including ankyrin-B syndrome. Additionally ankyrin-B levels have been shown to be significantly affected following myocardial infarction and sinus node dysfunction(SND).These findings suggest that ankyrin dysfunction has been associated with human cardiovascular disease phenotypes. Advances in ankyrin research will generate new insights into the molecular biological mechanisms to understand human cardiovascular disorders. In this review, we will briefly introduce recent ankyrin-B research advance in the cardiovascular system.

参考文献/References:

[1] Saito M, Watanabe-Nakayama T, Machida S, et al. Spectrin-ankyrin interaction mechanics: a key force balance factor in the red blood cell membrane skeleton[J]. Biophys Chem,2015,200-201:1-8.
[2] Jenkins PM, Kim N, Jones SL, et al. Giant ankyrin-G: a critical innovation in vertebrate evolution of fast and integrated neuronal signaling[J]. Proc Natl Acad Sci USA,2015,112(4):957-964.
[3] Wu HC, Yamankurt G, Luo J, et al. Identification and characterization of two ankyrin-B isoforms in mammalian heart[J]. Cardiovasc Res,2015,107(4):466-477.
[4] Mohler PJ, Davis JQ, Bennett V. Ankyrin-B coordinates the Na/K ATPase, Na/Ca exchanger, and InsP3 receptor in a cardiac T-tubule/SR microdomain[J]. PLoS Biol,2005,3(12):e423.
[5] Wang C, Wei Z, Chen K, et al. Structural basis of diverse membrane target recognitions by ankyrins[J]. Elife,2014,3. doi: 10.7554/eLife.04353.
[6] Cunha SR, Mohler PJ. Obscurin targets ankyrin-B and protein phosphatase 2A to the cardiac M-line[J]. J Biol Chem,2008,283(46):31968-31980.
[7] Baines AJ, Lu HC, Bennett PM. The protein 4.1 family: hub proteins in animals for organizing membrane proteins[J]. Biochim Biophys Acta,2014,1838(2):605-619.
[8] Robaei D, Ford T, Ooi SY. Ankyrin-B syndrome: a case of sinus node dysfunction, atrial fibrillation and prolonged QT in a young adult[J]. Heart Lung Circ,2015,24(2):e31-e34.
[9] Tester DJ, Ackerman MJ. Genetics of long QT syndrome[J]. Methodist Debakey Cardiovasc J,2014,10(1):29-33.
[10] Feldmann T, Shahar M, Baba A, et al. The Na(+)/Ca(2+)-exchanger: an essential component in the mechanism governing cardiac steroid-induced slow Ca(2+)oscillations[J]. Cell Calcium,2011,50(5):424-432.
[11] Camors E, Mohler PJ, Bers DM, et al. Ankyrin-B reduction enhances Ca spark-mediated SR Ca release promoting cardiac myocyte arrhythmic activity[J]. J Mol Cell Cardiol,2012,52(6):1240-1248.
[12] Wolf RM, Mitchell CC, Christensen MD, et al. Defining new insight into atypical arrhythmia: a computational model of ankyrin-B syndrome[J]. Am J Physiol Heart Circ Physiol,2010,299(5):H1505-H1514.
[13] Cunha SR, Hund TJ, Hashemi S, et al. Defects in ankyrin-based membrane protein targeting pathways underlie atrial fibrillation.[J]. Circulation,2011,124(11):1212-1222.
[14] Wolf RM, Glynn P, Hashemi S, et al. Atrial fibrillation and sinus node dysfunction in human ankyrin-B syndrome: a computational analysis[J]. Am J Physiol Heart Circ Physiol,2013,304(9):H1253-H1266.
[15] Curran J, Musa H, Kline CF, et al. Eps15 homology domain-containing protein 3 regulates cardiac T-type Ca2+ channel targeting and function in the atria[J]. J Biol Chem,2015,290(19):12210-12221.
[16] Hund TJ, Wright PJ, Dun W, et al. Regulation of the ankyrin-B-based targeting pathway following myocardial infarction[J]. Cardiovasc Res,2009,81(4):742-749.
[17] Liang X, Zhang Q, Cattaneo P, et al. Transcription factor ISL1 is essential for pacemaker development and function[J]. J Clin Invest,2015,125(8):3256-3268.
[18] Kline CF, Wright PJ, Koval OM, et al. betaⅣ-Spectrin and CaMKⅡ facilitate Kir6.2 regulation in pancreatic beta cells[J]. Proc Natl Acad Sci USA,2013,110(43):17576-17581.
[19] Li J, Kline CF, Hund TJ, et al. Ankyrin-B regulates Kir6.2 membrane expression and function in heart[J]. J Biol Chem,2010,285(37):28723-28730.
[20] Kashef F, Li J, Wright P, et al. Ankyrin-B protein in heart failure: identification of a new component of metazoan cardioprotection[J]. J Biol Chem,2012,287(36):30268-30281.
[21] Shen L, Chen C, Wei X, et al. Overexpression of ankyrin repeat domain 1 enhances cardiomyocyte apoptosis by promoting p53 activation and mitochondrial dysfunction in rodents[J]. Clin Sci(Lond),2015,128(10):665-678.
[22] Zhong L, Chiusa M, Cadar AG, et al. Targeted inhibition of ANKRD1 disrupts sarcomeric ERK-GATA4 signal transduction and abrogates phenylephrine-induced cardiomyocyte hypertrophy[J]. Cardiovasc Res,2015,106(2):261-271.
[23] Jasnic-Savovic J, Nestorovic A, Savic S, et al. Profiling of skeletal muscle Ankrd2 protein in human cardiac tissue and neonatal rat cardiomyocytes[J]. Histochem Cell Biol,2015,143(6):583-597.
[24] Bharath LP, Ruan T, Li Y, et al. Ceramide-initiated protein phosphatase 2A activation contributes to arterial dysfunction in vivo[J]. Diabetes,2015,64(11):3914-3926.
[25] Liu CC, Fry NA, Hamilton EJ, et al. Redox-dependent regulation of the Na(+)-K(+)pump: new twists to an old target for treatment of heart failure[J]. J Mol Cell Cardiol,2013,61:94-101.
[26] Stokke MK, Tovsrud N, Louch WE, et al. I(CaL)inhibition prevents arrhythmogenic Ca(2+)waves caused by abnormal Ca(2+)sensitivity of RyR or SR Ca(2+)accumulation[J]. Cardiovasc Res,2013,98(2):315-325.

相似文献/References:

[1]范新荣,等.心房颤动药物治疗的新靶点[J].心血管病学进展,2015,(5):584.[doi:10.3969/j.issn.1004-3934.2015.05.015]
　FAN Xinrong,ZENG Xiaorong,et al.Novel Targets of Pharmacological Therapies at Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(4):584.[doi:10.3969/j.issn.1004-3934.2015.05.015]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81370306) 作者简介:李子进(1991—),住院医师,在读硕士,主要从事心肌保护的研究。Email:2413481895@qq.com 通信作者:李景东,教授,主任医师,主要从事心脏电生理和心肌保护的研究。Email:jingdong-li@hust.edu.cn
更新日期/Last Update: 2016-07-25